Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive hiv-infected pregnant women in Rio de Janeiro, Brazil

AIDS Research and Human Retroviruses

Volumn 29, Issue 4, 2013, Pages 681-686

  Pilotto, José H ^a,b   Grinsztejn, Beatriz ^c   Veloso, Valdilea G ^c   Velasque, Luciane S ^c,d   Friedman, Ruth K ^c   Moreira, Ronaldo I ^c   Rodrigues Pedro, Adriana ^a   Oliveira, Sandra M ^b   Currier, Judith S ^e   Morgado, Mariza G ^a,f  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b HOSPITAL GERAL DE FORTALEZA   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Hospital General de Nova Iguaçu and Laboratório de AIDS e Imunologia Molecular   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BRAZIL; DISEASE TRANSMISSION; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMITTED DRUG RESISTANCE MUTATION; VIRUS GENOME;

ADULT; BRAZIL; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; MUTATION RATE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876222219     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0333     Document Type: Article

References (45)

1. MS. Recomendações para terapia anti-retroviral em adultos infectados pelo HIV 2007/2008; Comitêassesor em terapia anti-retroviral para adultos infectados pelo HIV.Secretaria de Vigilância em Saúde, Brasil. Ministério da Saúde, Brasil, 2008.
2. Marins JR, Jamal LF, Chen SY, et al.: Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS2003; 17(11):1675-1682.
3. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, and Moore RD: Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007;45(5):515-520.
4. Campos DP, Ribeiro SR, Grinsztejn B, et al.: Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. AIDS 2005;19(Suppl 4):S22-26.
5. Brigido L, Rodrigues R, Casseb J, et al.: CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: Partial control of viremia is associated with favorable outcome. AIDS Patient Care STDS 2004;18(4):189-198.
6. Brindeiro RM, Diaz RS, Sabino EC, et al.: Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically infected individuals. AIDS 2003;17(7): 1063-1069.
7. Geretti AM: New horizons in antiretroviral drug resistance. J HIV Ther 2007;12(4):81-82.
8. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41(4): 439-446.
9. Palma AC, Araujo F, Duque V, Borges F, Paixao MT, and Camacho R: Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007;7(3):391-398.
10. Booth CL and Geretti AM: Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007;59(6):1047-1056.
11. Gifford RJ, Liu TF, Rhee SY, et al.: The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009;25(9): 1197-1198.
12. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24(8):1596-1599.
13. Lole KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73(1): 152-160.
14. Coovadia H: Antiretroviral agents-how best to protect infants from HIV and save their mothers from AIDS. N Engl J Med 2004;351(3):289-292.
15. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, and Pitt J: Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007;44(3):329-335.
16. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, and Gulick RM: Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095. J Acquir Immune Defic Syndr 2007;46(5):547-554.
17. Paraskevis D, Magiorkinis E, Katsoulidou A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005;112 (1-2):115-122.
18. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966.
19. Lama JR, Sanchez J, Suarez L, et al.: Linking HIV and antiretroviral drug resistance surveillance in Peru: A model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006;42(4):501-505.
20. SPREAD: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. SPREAD Programme. AIDS 2008;22(5):625-635.
21. Vercauteren J, Derdelinckx I, Sasse A, et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24(3):355-362.
22. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004;9(6):829-848.
23. DHHS: Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. DHHS, U.S. Department of Health and Human Services, 2010: pp. 1-117.
24. DHHS: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services 2011( January 10, 2011): pp. 1-116.
25. de Ruiter A, Mercey D, Anderson J, et al.: British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9(7):452-502.
26. Gazzard BG, Anderson J, Babiker A, et al.: British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9(8): 563-608.
27. Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41(9):1316-1323.
28. Cardoso LP, Pereira GA, Viegas AA, Schmaltz LE, and Stefani MM: HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil. J Med Virol 2010;82(3):351-357.
29. Alcantara KC, Lins JB, Albuquerque M, et al.: HIV-1 motherto-child transmission and drug resistance among Brazilian pregnant women with high access to diagnosis and prophylactic measures. J Clin Virol 2012;54(1):15-20.
30. Gonsalez CR, Alcalde R, Nishiya A, et al.: Drug resistance among chronic HIV-1-infected patients naive for use of antiretroviral therapy in Sao Paulo city. Virus Res 2007;129(2): 87-90.
31. Inocencio LA, Pereira AA, Sucupira MC, et al.: Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009;12(1):20.
32. Sprinz E, Netto EM, Patelli M, et al.: Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses 2009;25(9):861-867.
33. Ferreira AS, Cardoso LP, and Stefani MM: Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil. J Med Virol 2011;83(8):1301-1307.
34. Dumans AT, Soares MA, Pieniazek D, et al.: Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 2002;46(9):3075-3079.
35. Sucupira MC, Caseiro MM, Alves K, et al.: High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS 2007;21(2):116-128.
36. Duran AS, Losso MH, Salomon H, et al.: Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007;21(2):199-205.
37. Viani RM, Hsia K, Hubbard P, et al.: Prevalence of primary HIV-1 drug resistance in pregnant women and in newly diagnosed adults at Tijuana General Hospital, Baja California, Mexico. Int J STD AIDS 2007;18(4):235-238.
38. Nyombi BM, Holm-Hansen C, Kristiansen KI, Bjune G, and Muller F: Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naive HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008;5:13.
39. Castelbranco EP, da Silva Souza E, Cavalcanti AM, Martins AN, de Alencar LC, and Tanuri A: Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola. AIDS Res Hum Retroviruses 2010;26(12): 1313-1316.
40. Ajoge HO, Gordon ML, Ibrahim S, Shittu OS, Ndung'u T, and Olonitola SO: Drug resistance pattern of HIV type 1 isolates sampled in 2007 from therapy-naive pregnant women in North-Central Nigeria. AIDS Res Hum Retroviruses 2012;28(1):115-118.
41. Hecht FM and Grant RM: Resistance testing in drug-naive HIV-infected patients: Is it time? Clin Infect Dis 2005;41(9): 1324-1325.
42. Garcia-Lerma JG and Heneine W: Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: Genotypic and phenotypic testing. J Clin Virol 2001;21(3):197-212.
43. Ghosn J, Pellegrin I, Goujard C, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20(2):159-170.
44. Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195(7):951-959.
45. Van Laethem K and Vandamme AM: Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev 2006;8(1):37-43.